AT406360T - Antagonist of opioid receptors - Google Patents

Antagonist of opioid receptors

Info

Publication number
AT406360T
AT406360T AT04716082T AT04716082T AT406360T AT 406360 T AT406360 T AT 406360T AT 04716082 T AT04716082 T AT 04716082T AT 04716082 T AT04716082 T AT 04716082T AT 406360 T AT406360 T AT 406360T
Authority
AT
Austria
Prior art keywords
antagonist
opioid receptors
opioid
receptors
Prior art date
Application number
AT04716082T
Other languages
German (de)
Inventor
Maria Blanco-Pillado
Dana Benesh
Charles Mitch
Kumiko Tackeuchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US45324303P priority Critical
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AT406360T publication Critical patent/AT406360T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58One oxygen atom, e.g. butenolide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms
AT04716082T 2003-03-07 2004-03-01 Antagonist of opioid receptors AT406360T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US45324303P true 2003-03-07 2003-03-07

Publications (1)

Publication Number Publication Date
AT406360T true AT406360T (en) 2008-09-15

Family

ID=32990743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04716082T AT406360T (en) 2003-03-07 2004-03-01 Antagonist of opioid receptors

Country Status (12)

Country Link
US (1) US7396943B2 (en)
EP (1) EP1606275B1 (en)
JP (1) JP2006519855A (en)
CN (1) CN1753884A (en)
AT (1) AT406360T (en)
AU (1) AU2004220113A1 (en)
BR (1) BRPI0408108A (en)
CA (1) CA2513791A1 (en)
DE (1) DE602004016127D1 (en)
ES (1) ES2312972T3 (en)
MX (1) MXPA05009367A (en)
WO (1) WO2004080996A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
PT2208727E (en) * 2002-09-19 2012-10-11 Lilly Co Eli Diaryl ethers as opioid receptor antagonist
EP1615646B1 (en) 2003-04-08 2014-12-24 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
CN1802375A (en) * 2003-04-09 2006-07-12 千禧药品公司 Beta-carbolines useful for treating inflammatory disease
EP1697307B1 (en) 2003-12-12 2014-03-12 Eli Lilly & Company Opioid receptor antagonists
WO2005066164A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Opioid receptor antagonists
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402137D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
AT399164T (en) 2004-03-12 2008-07-15 Lilly Co Eli Antagonist of opioid receptor
DE602005022572D1 (en) 2004-03-12 2010-09-09 Lilly Co Eli Antagonist of opioid receptor
AT545413T (en) 2004-03-15 2012-03-15 Lilly Co Eli Antagonist of opioid receptor
AT420858T (en) 2004-03-15 2009-01-15 Lilly Co Eli 4- (5- (aminomethyl) -indol-1- ylmethyl) benzamide derivatives and related compounds obesity as opioid receptor antagonists for the treatment of
CA2594860A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN104248763A (en) * 2005-03-07 2014-12-31 芝加哥大学 Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc Synthesis (s) -n-methylnaltrexone, pharmaceutical compositions and uses
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc Synthesis of (R) -N-methylnaltrexone, PHARMACEUTICAL COMPOSITIONS AND USES
CN101331120A (en) 2005-10-13 2008-12-24 史密丝克莱恩比彻姆公司 Novel heterocycle compounds
CN101511808A (en) 2006-09-08 2009-08-19 辉瑞产品公司 Diaryl ether derivatives and uses thereof
DK2565195T3 (en) 2007-03-29 2015-06-29 Wyeth Llc And peripheral opioid receptor antagonists, and uses thereof
EP3263571A1 (en) 2007-03-29 2018-01-03 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
WO2008142454A1 (en) 2007-05-22 2008-11-27 Prosidion Limited Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
EP2197835A1 (en) 2007-09-07 2010-06-23 Prosidion Limited Bicyclic aryl and heteroaryl receptor modulators
AU2009206653B2 (en) * 2008-01-22 2013-07-18 Eli Lilly And Company Kappa selective opioid receptor antagonist
JP5358587B2 (en) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッドProgenics Pharmaceuticals, Inc. (R), (r) -2,2'- bis - methylnaltrexone production and use
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN102325777B (en) * 2009-02-23 2015-08-12 马林克罗特公司 (+) - morphinan * n- oxide and preparation method
BR112012006069A2 (en) * 2009-09-18 2016-03-29 Adolor Corp method for treating or preventing induced constipation and opioid-induced bowel dysfunction in a human, and the use of a therapeutically effective amount of compound
US9751847B2 (en) 2010-10-14 2017-09-05 University Of Utah Research Foundation Methods and compositions related to neuroactive thiazoline compounds
CN106117195A (en) * 2016-06-09 2016-11-16 青岛辰达生物科技有限公司 Synthetic method of medicine namely parecoxib sodium for treating leukaemia
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
AUPP796798A0 (en) * 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
HU0303538A2 (en) 2000-12-21 2005-02-28 Bristol-Myers Squibb Co. Tec family tyrosine kinase inhibitors and pharmaceutical compositions containing these compounds thiazolyl
KR100894189B1 (en) 2001-03-29 2009-04-22 일라이 릴리 앤드 캄파니 N-2-ArylethylBenzylamines as Antagonists of the 5-HT6 Receptor

Also Published As

Publication number Publication date
US7396943B2 (en) 2008-07-08
EP1606275A1 (en) 2005-12-21
EP1606275B1 (en) 2008-08-27
CA2513791A1 (en) 2004-09-23
MXPA05009367A (en) 2005-11-04
AU2004220113A1 (en) 2004-09-23
JP2006519855A (en) 2006-08-31
WO2004080996A1 (en) 2004-09-23
CN1753884A (en) 2006-03-29
DE602004016127D1 (en) 2008-10-09
BRPI0408108A (en) 2006-03-01
ES2312972T3 (en) 2009-03-01
US20060166987A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
AT506317T (en) base unit
AT481106T (en) Heterocyclic sulfonamide-hepatitis C virus-inhibitor
DE60330694D1 (en) Pyrimidopyrimidone as kinase inhibitors
IS7939A (en) Pýrasólpýridín derivatives
AT328871T (en) 4-phenyl-pyridine derivatives useful as antagonists of neurokinin-1 receptor
IS8110A (en) Quinoline derivatives which inhibit phosphodiesterase
RU2005132961A (en) Tetragidroizohinolilatsetamida derivatives and their use as orexin receptor antagonists
AT494285T (en) Muscarinic acetylcholine receptor antagonists
IS8108A (en) new compounds
IS7066A (en) Piperadine derivatives as NMDA receptor antagonists
AT426599T (en) Thiazolylpiperidin derivatives as inhibitors mtp
DE60309481D1 (en) Cyclic n-aroylamine as orexin receptor antagonists
DE602005027067D1 (en) Detection of chromosomal disorders
DE60336858D1 (en) ch hydrogenation
DK1495018T3 (en) tricyclic thrombin receptor antagonists
AT302196T (en) N-adamantylalkyl benzamide derivative antagonists as p2x7- receptor
AT286897T (en) Morpholine derivatives as antagonists of orexin receptors
DE602006018301D1 (en) Histamine-3 receptor antagonists
IS8578A (en) 3- carbamoyl - 2- pyridone derivatives
IS8472A (en) Triazole derivatives as vasopressin antagonists
AT450533T (en) carboxamide
AT502009T (en) Cb1-modulator compounds
IS8323A (en) new amínóbensófenónefnasambönd
IS8348A (en) Fused heteróhringasambönd
AT540936T (en) Substituted 2-alkyl-quinazolinone derivatives as PARP inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties